Lindsey Te Ata o Tu MacDonald AHRECS, Consultant In New Zealand, we have two separate drivers for change in
“Reminder about service options and an easy way to pay AHRECS,” we say… aware of how corporate sleazy that sounds
Dr Gary Allen, Senior Consultants AHRECS Prof. Mark Israel Prof. Colin Thomson AM . Just in time for the end of the
It is with great sorrow that we note the passing of one of our consultants, Barry Smith. Of Te Rarawa
Jay Marlowe and Martin Tolich have had an article published (in press) in Research Ethics examining the first year of
In this thought-provoking post, Nik Zeps (a consultant with AHRECS and a partner at Chrysalis) discusses the serious harm (in terms of reputation and career, as well as lost useful lines of inquiry) when there are complaints that allege ethical problems with clinical research.
These relate to situations where the clinical research is evaluating different kinds of intervention, where the evidence for the ‘accepted’ treatment might not be clear.
A misunderstanding of such research designs and a visceral reaction to apparent breaches aren’t helpful.
When such allegations are made, the researchers are rarely afforded an opportunity to respond and explain. If they were, one assumes that the manner could be easily cleared up.
We are embarrassed to admit in our own reporting of the cited case we really didn’t grasp the realities of what occurred or called out the very emotive reaction.
We’re preparing to work on a new version of the subscribers’ area, so we’d
Nik Zeps, Consultant, AHRECS Keywords: Ethical Review, International Guidelines, Gene editing technologies, It has
Paul M Taylor1 and Daniel P Barr2 1Director, Research Integrity, Governance and Systems Research